Navigation Links
PharmaNet Development Group Experts to Share Insights at the 9th Annual Partnerships in Clinical Trials Conference in Vienna
Date:11/1/2010

PRINCETON, N.J., Nov. 1, 2010 /PRNewswire/ -- PharmaNet Development Group, Inc., a leading provider of clinical development services to pharmaceutical, biotechnology, generic drug and medical device companies, today announced its experts will share their insights on key industry topics during the 9th Annual Partnerships in Clinical Trials Conference taking place from 16-19 November at Reed Messe in Vienna, Austria.  

At the conference, members of PharmaNet's management team will discuss the opportunities and challenges currently facing the CRO industry, including the impact of the economic environment on drug development and the need for innovative collaboration in post-marketing studies and biosimilar development.  

Wednesday 17 November 2010 Dalvir Gill, PhD, President, Late Stage Development, will give a keynote presentation, "Surviving Difficult Times: How Much Has the Recession Really Affected Clinical Outsourcing and How Does the Industry Need to Change?"

Jeff Trotter, Executive Vice President, Phase IV Development, will present "Successful Approaches to Partnering in Post-Marketing Studies."

Thursday 18 November 2010Dr. Pablo Fernandez, LMS, FFPM, Senior Vice President, Medical Affairs, will present "Partnering to Overcome the Challenges of Biosimilar Development."

Conference attendees can learn more about PharmaNet's capabilities by visiting booth 129 in the exhibition hall where an international team of representatives will be available to discuss PharmaNet's expertise in helping clients reach their goal of delivering safe and effective therapeutics to patients.

About PharmaNet Development Group, Inc.PharmaNet Development Group, a recognized leader of global drug development services to the pharmaceutical, biotechnology, generic drug, and medical device industries, provides comprehensive capabilities in Phase I-IV clinical development, bioanalytical and bioequivalence services, regulatory, staffing, and therapeutic solutions. For the applied knowledge and intelligent solutions needed to accelerate drug development programs of all sizes around the world, PharmaNet works for you. For more information, please visit www.PharmaNet.com. Contact: Anne-Marie HessPhone:   (609) 951-6842E-mail:   ahess@pharmanet.com
'/>"/>

SOURCE PharmaNet Development Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. PharmaNet Development Group Appoints Anthony Maida, Vice President, Clinical Research
2. Stephen Kasay Joins PharmaNet Development Group as Chief Information Officer
3. SEC Closes Investigation of PharmaNet Development Group and Recommends No Action
4. Christopher Brennan Joins PharmaNet Development Group as General Counsel
5. PharmaNet Development Group Provides Financial Update and Announces Geographic Expansion
6. PharmaNet Development Group Clinical Research Experts to Present at Global Professional Meetings in June
7. PharmaNet Development Group Gives Notice of Anticipated Fundamental Change and Merger to Holders of Its Convertible Notes
8. PharmaNet Development Group, Inc. Expands Latin America Operations with Opening of Brazil Office
9. An Affiliate of JLL Partners, Inc. Commences Cash Tender Offer to Acquire PharmaNet Development Group, Inc. at $5.00 per Share
10. PharmaNet Development Group Agrees to be Acquired by JLL Partners
11. Thrombosis Experts Present Update on Important New Developments in Anticoagulation Management
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... ... 03, 2016 , ... Microbial genomics leader uBiome is awarding ... been made to Dr. Renato Polimanti of Yale University School of Medicine, who ... Grant proposals have been vetted by the company’s scientific review committee. , ...
(Date:12/2/2016)... ... 2016 , ... In anticipation of AxioMed’s exclusive cleanroom manufacturing ... President, Jake Lubinski will be traveling to Switzerland from December 5-10. Mr. Lubinski ... and Zurich to discuss the benefits of a viscoelastic disc. AxioMed received CE ...
(Date:12/2/2016)... Amgen (NASDAQ: AMGN ) and Allergan ... of a Marketing Authorization Application (MAA) to the European Medicines ... ® (bevacizumab). The companies believe this submission is the ... "The submission of ABP 215 to the EMA is ... portfolio," said Sean E. Harper , M.D., executive vice ...
(Date:12/2/2016)... ... 2016 , ... ACEA Biosciences, Inc. announced today that it will be presenting ... the World Conference on Lung Cancer 2016, taking place in Vienna, Austria December 3rd-8th. ... trials for AC0010 in patients with advanced non-small cell lung cancer harboring the EGFR ...
Breaking Biology Technology:
(Date:11/22/2016)... MINNETONKA, Minn. , Nov. 22, 2016   ... that supports the entire spectrum of clinical research, is ... by Medical LiveWire Healthcare and Life Sciences Awards ... This award caps off an unprecedented year of recognition ... clinical trials for over 15 years. iMedNet ...
(Date:11/17/2016)... -- Global Market Watch: Primarily supported by ownership ... and Academics) market is to witness a value of US$37.1 ... highest Compounded Annual Growth Rate (CAGR) of 10.75% is foreseen ... period 2014-2020. North America is not ... Europe at 9.56% respectively. Report Focus: ...
(Date:11/15/2016)... ROCKVILLE, Md. , Nov. 15, 2016 /PRNewswire/ ... clinical company developing therapeutics focused on the gut ... public offering of 25,000,000 shares of its common ... its common stock at a price to the ... gross proceeds to Synthetic Biologics from the offering, ...
Breaking Biology News(10 mins):